Loading clinical trials...
Loading clinical trials...
A Phase Ib/II Study of ST-1898 to Evaluate the Efficacy and Safety in Patients With Renal Cell Carcinoma (RCC)
Conditions
Interventions
ST-1898 tablets
Locations
1
China
Peking University Cancer Hospital & Institute
Beijing, Beijing Municipality, China
Start Date
February 7, 2023
Primary Completion Date
December 1, 2025
Completion Date
December 1, 2025
Last Updated
August 24, 2025
NCT05969860
NCT06863311
NCT07227415
NCT05868174
NCT04071223
NCT05122546
Lead Sponsor
Beijing Scitech-Mq Pharmaceuticals Limited
Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions